Clemens Unger

Universidade Federal do Paraná — Brazil

Medicine · Health Sciences

56h-index9.9kcitations287works3.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Treatment and Pharmacology(51), Organophosphorus compounds synthesis(27), Angiogenesis and VEGF in Cancer(26), Nanoparticle-Based Drug Delivery(18), Cancer, Hypoxia, and Metabolism(16)

Publications285 total

Design and early progress of the Comparison of Anticoagulation and anti-Platelet Therapies for Intracranial Vascular Atherostenosis (CAPTIVA) trial
International Journal of Stroke·2024· 4 citedOpen Access
Structure and optical properties of Cu2O nanocrystals in a sodium-borate glass
Ceramics International·2024· 2 cited
Supplementary Figure 1 from A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Figure Legend from A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors
2023Open Access
Data from A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Figure 1 from A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors
2023Open Access
Data from A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Table 1 from A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Table 1 from A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Figure Legend from A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors
2023Open Access
Kardiologische Komplikationen unter Tumortherapie
TumorDiagnostik & Therapie·2020
988TiP: ARIEL4: An international, randomised phase 3 study of the PARP inhibitor rucaparib vs chemotherapy for the treatment of BRCA-mutated, relapsed, high-grade ovarian cancer
UCL Discovery (University College London)·2017
Dietary supplementation with n-3-fatty acids in patients with pancreatic cancer and cachexia: marine phospholipids versus fish oil - a randomized controlled double-blind trial
Lipids in Health and Disease·2017· 79 citedOpen Access
Hexadecylphosphocholine and Octadecyl-methyl-glycero-3-phosphocholine: A Comparison of Hemolytic Activity, Serum Binding and Tissue Distribution
Progress in tumor research·2015· 64 cited
Hexadecylphosphocholine in Liposomal Dispersions
Progress in tumor research·2015· 10 cited
Determination of Alkylphosphocholines and of Alkyl-glycero-phosphocholines in Biological Fluids and Tissues
Progress in tumor research·2015· 10 cited
Hexadecylphosphocholine Amplifies the Effect of Granulocyte Colony-Stimulating Factor on Differentiating Hematopoietic Progenitor Cells
Progress in tumor research·2015· 6 cited
Cellular Uptake and Metabolic Fate of Hexadecylphosphocholine
Progress in tumor research·2015· 17 cited
Subject Index
Progress in tumor research·2015
Comparison of the Tissue Distribution of Hexadecylphosphocholine and Erucylphosphocholine
Progress in tumor research·2015· 4 cited
page 1 of 15Next →

Frequent Co-authors

Joachim Drevs(16), K. Mross(12), Felix Kratz(11), Michael Medinger(7), N. Esser(6), H. Eibl(6), Dieter Marmé(5), Ulrich Massing(5), Simone Steinbild(4), Annette Frost(3), Ralph Strecker(3), Ute Zirrgiebel(3), Iduna Fichtner(3), Maren Rautenberg(3), Dirk Laurent(3), Ulrich Beyer(3), Thomas Roth(3), Peter Schumacher(3), W. H. Hoffmann(3), Heinz H. Fiebig(3)